Epilepsy with Myoclonic-Atonic Seizures Overview

Save information for later
Sign Up

Learn About Epilepsy with Myoclonic-Atonic Seizures

What is the definition of Epilepsy with Myoclonic-Atonic Seizures?
Epilepsy with myoclonic-atonic seizures is a rare epilepsy syndrome of early childhood. It is characterized by seizures of many different types, most often myoclonic-atonic, astatic, or generalized tonic-clonic seizures. Seizures can be followed by drop attacks, which can lead to falls and injuries. Absence seizures may occur. People with the condition may experience several seizures each day. The epilepsy may result in a delay or regression of skills. Autistic features and ataxic (poorly controlled) movements have been reported in some cases. Changes in the SCN1A, SCN1B, GABRG2, CHD2, and SLC6A1 genes can cause or contribute to Epilepsy with myoclonic-atonic seizures. However, in many cases the cause remains unknown. Epilepsy with myoclonic-atonic seizures can be inherited from an affected parent or occur for the first time in a family as a sporadic disease.
What are the alternative names for Epilepsy with Myoclonic-Atonic Seizures?
  • Epilepsy with myoclonic-atonic seizures
  • Doose syndrome
  • Epilepsy with myoclonic-astatic seizures
  • Epilepsy with myoclono-astatic crisis
  • Myoclonic astatic epilepsy
Who are the top Epilepsy with Myoclonic-Atonic Seizures Local Doctors?
Elite in Epilepsy with Myoclonic-Atonic Seizures
Dr. Orrin Devinsky
Neurology | General Surgery
Elite in Epilepsy with Myoclonic-Atonic Seizures
Dr. Orrin Devinsky
Neurology | General Surgery

New York University

223 E 34th St, 
New York, NY 
646-558-0800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Orrin Devinsky is a Neurologist and a General Surgeon in New York, New York. Dr. Devinsky is rated as an Elite provider by MediFind in the treatment of Epilepsy with Myoclonic-Atonic Seizures. His top areas of expertise are Myoclonic Epilepsy, Dravet Syndrome, Seizures, Epilepsy, and Deep Brain Stimulation.

Elite in Epilepsy with Myoclonic-Atonic Seizures
Dr. Jack Parent
Neurology
Elite in Epilepsy with Myoclonic-Atonic Seizures
Dr. Jack Parent
Neurology

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
734-936-9020
Languages Spoken:
English
See accepted insurances

Jack Parent is a Neurologist in Ann Arbor, Michigan. Dr. Parent is rated as an Elite provider by MediFind in the treatment of Epilepsy with Myoclonic-Atonic Seizures. His top areas of expertise are Myoclonic Epilepsy, Epilepsy, Epilepsy with Myoclonic-Atonic Seizures, and Dravet Syndrome.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Epilepsy with Myoclonic-Atonic Seizures
Dr. Javier A. Echeverri
Neurology
Distinguished in Epilepsy with Myoclonic-Atonic Seizures
Dr. Javier A. Echeverri
Neurology

St. Vincent Neurosurgery

1041 North 29th Street, 
Billings, MT 
406-237-5577
Experience:
47+ years
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Javier Echeverri is a Neurologist in Billings, Montana. Dr. Echeverri has been practicing medicine for over 47 years and is rated as a Distinguished provider by MediFind in the treatment of Epilepsy with Myoclonic-Atonic Seizures. His top areas of expertise are Essential Tremor, Parkinson's Disease, Movement Disorders, Epilepsy with Myoclonic-Atonic Seizures, and Deep Brain Stimulation. Dr. Echeverri is currently accepting new patients.

View All Doctors
What are the latest Epilepsy with Myoclonic-Atonic Seizures Clinical Trials?
A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures
A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures
Enrollment Status: Recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).

Match to trials
Find the right clinical trials for you in under a minute
Get started
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation
Enrollment Status: Recruiting
Publish Date: November 26, 2025

Summary: Dravet syndrome with SCN1A gene mutation is a developmental and epileptic encephalopathy characterized by treatment-resistant epilepsy and global developmental delay. Despite the considerable attention recently Dravet syndrome (DS) in drug development, studies characterising the progression of the neurodevelopmental phenotype over time remain limited. In particular, many previous studies of natura...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center